Your browser doesn't support javascript.
loading
Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus.
Jakeman, Bernadette; Scherrer, Alexandra U; Darling, Katharine E A; Damas, Jose; Bieler-Aeschlimann, Melanie; Hasse, Barbara; Schlosser, Ladina; Hachfeld, Anna; Gutbrod, Klemens; Tarr, Philip E; Calmy, Alexandra; Assal, Frederic; Kunze, Ursula; Stoeckle, Marcel; Schmid, Patrick; Toller, Gianina; Rossi, Stefania; di Benedetto, Caroline; du Pasquier, Renaud; Cavassini, Matthias; Marzolini, Catia.
Afiliación
  • Jakeman B; Department of Pharmaceutical Practice and Administrative Sciences, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA.
  • Scherrer AU; Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Darling KEA; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Damas J; Departments of Medicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Bieler-Aeschlimann M; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Hasse B; Service of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
  • Schlosser L; Service of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
  • Hachfeld A; Service of Neurology, Department of Neurosciences, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland.
  • Gutbrod K; Departments of Medicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Tarr PE; Department of Neuropsychology, Neurology Clinic, University Hospital Zurich, Zurich, Switzerland.
  • Calmy A; Department of Infectious Diseases, University Hospital Bern, University of Bern, Bern, Switzerland.
  • Assal F; Department of Neurology, University Hospital Bern, University of Bern, Neurozentrum Bern, Switzerland.
  • Kunze U; University Department of Medicine, Kantonsspital Bruderholz, University of Basel, Basel, Switzerland.
  • Stoeckle M; Division of Infectious Diseases, University Hospital Geneva, University of Geneva, Geneva, Switzerland.
  • Schmid P; Service of Neurology, University Hospital Geneva, University of Geneva, Geneva, Switzerland.
  • Toller G; Memory Clinic, Felix Platter Hospital University Center for Medicine of Aging, Basel, Switzerland.
  • Rossi S; Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • di Benedetto C; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • du Pasquier R; Department of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
  • Cavassini M; Neuropsychology Unit, Department of Neurology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
  • Marzolini C; Neuropsychology and Speech Therapy Unit, Neurocenter of Southern Switzerland, Regional Hospital Lugano, Lugano, Switzerland.
Open Forum Infect Dis ; 9(9): ofac457, 2022 Sep.
Article en En | MEDLINE | ID: mdl-36147598
ABSTRACT

Background:

We previously showed that anticholinergic (ACH) medications contribute to self-reported neurocognitive impairment (NCI) in elderly people with human immunodeficiency virus (PWH). The current cross-sectional study further evaluated the effect of ACH and sedative drugs on neurocognitive function in PWH who underwent comprehensive neuropsychological evaluation.

Methods:

A medication review was performed in PWH enrolled in the prospective Neurocognitive Assessment in Metabolic and Aging Cohort within the Swiss HIV Cohort Study. Neurocognitive functions were analyzed in 5 domains (motor skills, speed of information, attention/working memory, executive functions, and verbal learning memory). The effect of ACH and sedative medications on neurocognitive functioning was evaluated using linear regression models for the continuous (mean z-score) outcome and multivariable logistic regression models for the binary (presence/absence) outcome.

Results:

A total of 963 PWH (80% male, 92% Caucasian, 96% virologically suppressed, median age 52) were included. Fourteen percent of participants were prescribed ≥1 ACH medication and 9% were prescribed ≥1 sedative medication. Overall, 40% of participants had NCI. Sedative medication use was associated with impaired attention/verbal learning and ACH medication use with motor skills deficits both in the continuous (mean z-score difference -0.26 to -0.14, P < .001 and P = .06) and binary (odds ratio [OR], ≥1.67; P < .05) models. Their combined use was associated with deficits in overall neurocognitive functions in both models (mean z-score difference -0.12, P = .002 and OR = 1.54, P = .03). These associations were unchanged in a subgroup analysis of participants without depression (n = 824).

Conclusions:

Anticholinergic and sedative medications contribute to NCI. Clinicians need to consider these drugs when assessing NCI in PWH.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Open Forum Infect Dis Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Open Forum Infect Dis Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
...